Development of biomarkers for Huntington's disease

Biomarkers for Huntington's disease: an update

“…Altered metabolite profiles, suggested of neuronal dysfunction have also been reported in early HD and treatments aiming to improve neuronal health might effectively be assessed using such a metric [11]. Again, further cross-site validation and follow-up data is required to assess the utility of these modalities.…”

Computational Investigations of Cognitive Impairment in Huntington's Disease

“…This assumes that physician's accuracy in determining the clinical status of an individual is infallible. As Aylward (2006) discusses, this is seldom the case and much research remains needed to find objective biomarkers that help pinpoint the disease onset (Weir, et al, 2011). One such objective measure is striatal volume loss (Aylward, 2006).…”

Cognition in Huntington's Disease

“…Clinical trials of putative disease-modifying treatments in preclinical HD mutation carriers are needed. Such trials will need to assess HD carriers serially with both neuropsychological and neuroimaging tests, as well as other more specific biomarkers (Weir et al, 2011). Public and philanthropic funds will be needed for the development of therapies for HD as its low-prevalence status is unlikely to drive sufficient entrepreneurial interest.…”